MedTrace Logo

Evaluate the Safety and Efficacy of Combination Therapy With SYS6090 Injection for Hepatocellular Carcinoma

NCT07761286 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 288

Last updated 2026-08-12

No results posted yet for this study

Summary

This is an open-label, multicenter Phase Ib/II clinical study designed to evaluate the safety, tolerability, and efficacy of combination therapy with SYS6090 Injection in participants with hepatocellular carcinoma (HCC).

Conditions

  • HCC - Hepatocellular Carcinoma

Interventions

DRUG

SYS6090 Injection + Bevacizumab Injection

SYS6090 in Combination with Bevacizumab 15mg/kg

DRUG

SYS6090 Injection +SYS6043 Injection +Bevacizumab Injection

SYS6090 in Combination with SYS6043 and Bevacizumab 15mg/kg

DRUG

Bevacizumab Injection + Sintilimab Injection

Bevacizumab 15mg/kg in Combination with Sintilimab 200mg, intravenous infusion, every 3 weeks.

Sponsors & Collaborators

  • CSPC Megalith Biopharmaceutical Co.,Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-30
Primary Completion
2029-09-30
Completion
2031-09-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07761286 on ClinicalTrials.gov